estradiol + fenretinide

Estradiol + fenretinide is an experimental combination therapy consisting of estradiol, a natural estrogen hormone, and fenretinide, a synthetic retinoid. Estradiol acts primarily as an agonist at the estrogen receptor to provide hormonal effects such as relief of menopausal symptoms and modulation of lipid profiles. Fenretinide is known for its antineoplastic properties; it induces apoptosis in cancer cells and has been studied for chemoprevention in breast and endometrial cancers. The combination has been evaluated in clinical trials for its impact on cardiovascular risk biomarkers and potential cancer prevention benefits in postmenopausal women receiving hormone replacement therapy[2][3]. Fenretinide modifies some cardiovascular risk markers when combined with estradiol, potentially offering a safer profile compared to other retinoids[2].